Loading...
Loading...
Clinical performance tests showed a high correlation with clinical severity of atopic dermatitis.
These values may fluctuate under various conditions, such as the number of subjects in the
target group and the age group. Therefore, diagnosis and severity assessment of atopic
dermatitis should primarily be based on the observation and evaluation of individual rashes, with the serum SCCA2 value also serving as one indicator for a comprehensive judgment.
| Serum SCCA2 value | Median | |
|---|---|---|
| Reference standard range | <1.6 ng/mL | 0.8 |
| Mild disease | ≥1.6 ng/ mL and< 2.6 ng/mL | 2.0 |
| Moderate disease | ≥2.6 ng /mL and < 6.0 ng/mL | 3.5 |
| Severe disease | 6.0 ≥ ng/mL | 10.8 |
The serum SCCA2 levels of 159 non-allergic patients aged 0 to 15 years and 176 patients with atopic dermatitis were tabulated and analyzed.
Objective-SCORAD (O-SCORAD) was used as an index of the severity of atopic skin irritation, and scores of less than 15 were classified as minor, 15 or more than 40 as moderate, and 40 or more as severe.
Serum SCCA2 levels were significantly higher depending on the severity of atopic dermatitis. On the other hand, the serum TARC and total IgE levels of the control test items were generally high depending on the severity, but did not differ significantly between mild and moderate disease.
Serum SCCA2 levels were suggested to be significantly higher than conventional serum tests, reflecting the severity of the disease.
| SCCA2 | TARC | IgE | |||||
|---|---|---|---|---|---|---|---|
| Severity | Number of cases | Median (ng/mL) |
p-value | Median (pg/mL) |
p-value | Median (IU/mL) |
p-value |
| Non-allergic child | 159 (IgE 151) |
0.8 | - | 341 | - | 39.4 | - |
| Mild disease | 56 | 2.0 | 1)<0.001 | 885 | <0.001 | 282 | <0.001 |
| Moderate disease | 60 | 3.5 | 2)<0.01 | 897 | NS | 652 | NS |
| Serious disease | 60 | 10.8 | 3)<0.001 | 2530 | <0.001 | 1869 | <0.001 |
1)vs Non-allergic 2)vs Minor illness 3)vs Moderate disease
NS:p>0.05 (Steel-Dwass)
